News Release

和其瑞医药任命陈曦为首席执行官

和其瑞医药宣布首创单抗新药HMI-115获得治疗子宫内膜异位症的 中国临床二期试验批准

Circ Res 北京大学肖瑞平教授团队揭示阻断MG53 S255磷酸化可以保护糖尿病心脏免受缺血性损伤

Hope Medicine Announces US FDA Clearance for Phase II Clinical Trial of A First-in-class Monoclonal Antibody, HMI-115, in AGA Alopecia

Hope Medicine completed US$56 million in Series B financing, strengthening capabilities of global innovation

Hope Medicine announced global license agreement with Bayer AG to advance the development and commercialization of the monoclonal antibody directed against prolactin (PRL) receptor